Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity

In vivo binding of a tau imaging probe, [ 11 C]PBB3, in patients with progressive supranuclear palsy

(2019) Hironobu Endo et al.   MOVEMENT DISORDERS

Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases

(2019) Matthew J Betts et al.   BRAIN

Profound degeneration of wake-promoting neurons in Alzheimer's disease

(2019) Jun Oh et al.   Alzheimers & Dementia

Neurotransmitter deficits from frontotemporal lobar degeneration

(2018) Alexander G Murley et al.   BRAIN

Selective Vulnerability of Brainstem Nuclei in Distinct Tauopathies: A Postmortem Study

(2018) Rana A Eser et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

[11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy

(2018) Luca Passamonti et al.   NEUROLOGY

Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease

(2018) David Weinshenker   TRENDS IN NEUROSCIENCES

Commentary: Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice

(2018) Matthew J. Betts et al.   Frontiers in Neuroscience

MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy

(2018) Jennifer L. Whitwell et al.   MOVEMENT DISORDERS

In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults

(2017) Matthew J. Betts et al.   NEUROIMAGE

Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff

(2017) Heiko Braak et al.   Journal of Parkinsons Disease

Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease

(2017) Sarah C. Kelly et al.   Acta Neuropathologica Communications

Progression of brain atrophy in PSP and CBS over 6 months and 1 year

(2016) Shubir Dutt et al.   NEUROLOGY

Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes

(2016) Ian T.S. Coyle-Gilchrist et al.   NEUROLOGY

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson’s Disease

(2016) Robin J Borchert et al.   NEUROPSYCHOPHARMACOLOGY

Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy

(2016) Richard M. Tsai et al.   PARKINSONISM & RELATED DISORDERS

Improving Response Inhibition in Parkinson’s Disease with Atomoxetine

(2015) Zheng Ye et al.   BIOLOGICAL PSYCHIATRY

Norepinephrine and its metabolites are involved in the synthesis of neuromelanin derived from thelocus coeruleus

(2015) Kazumasa Wakamatsu et al.   JOURNAL OF NEUROCHEMISTRY

Early neurone loss in Alzheimer’s disease: cortical or subcortical?

(2015) Thomas Arendt et al.   Acta Neuropathologica Communications

Targeting impulsivity in Parkinson’s disease using atomoxetine

(2014) Angie A. Kehagia et al.   BRAIN

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

(2014) Adam L Boxer et al.   LANCET NEUROLOGY

Noradrenergic modulation of cognition: Therapeutic implications

(2013) Samuel R Chamberlain et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Modeling trajectories of regional volume loss in progressive supranuclear palsy

(2013) Keith A. Josephs et al.   MOVEMENT DISORDERS

Neural reserve, neuronal density in the locus ceruleus, and cognitive decline

(2013) R. S. Wilson et al.   NEUROLOGY

The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease

(2012) Elena M. Vazey et al.   Frontiers in Behavioral Neuroscience

Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

(2011) Heiko Braak et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

The pathological process underlying Alzheimer’s disease in individuals under thirty

(2010) Heiko Braak et al.   ACTA NEUROPATHOLOGICA

Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges

(2009) David R Williams et al.   LANCET NEUROLOGY

Neuromelanin Activates Microglia and Induces Degeneration of Dopaminergic Neurons: Implications for Progression of Parkinson’s Disease

(2009) Wei Zhang et al.   NEUROTOXICITY RESEARCH